Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: NASDAQ CM
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

Corcept Therapeutics Inc

+ Add to Watchlist

CORT:US

3.6100 USD 0.1300 3.74%

As of 17:20:00 ET on 03/05/2015.

Snapshot for Corcept Therapeutics Inc (CORT)

Open: 3.4300 Day's Range: 3.4200 - 3.7900 Volume: 130,218
Previous Close: 3.4800 52wk Range: 1.6900 - 4.4900 1-Yr Rtn: -9.75%

Stock Chart for CORT

No chart data available.
  • CORT:US 3.6200
  • 1D
  • 1M
  • 1Y
3.4800
Interactive CORT Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for CORT

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) -0.3100
Est. EPS (USD) (12/2015) -0.1130
Est. PEG Ratio -
Market Cap (M USD) 368.33
Shares Outstanding (M) 101.19
30 Day Average Volume 115,834
Price/Book (mrq) -
Price/Sale (ttm) 13.7384
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 05/07/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for CORT

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for CORT

Corcept Therapeutics Inc. is a pharmaceutical company that discovers and develops drugs for the treatment of severe metabolic and psychiatric disorders. The Company's lead product modulates the effect of cortisol, also known as the "stress hormone", by selectively blocking the binding of cortisol to one of its two known receptors, the GR-II receptor.

Joseph K BelanoffPresident/CEO/Co-FounderGary Charles Robb "Charlie"CFO/Secretary
Steven LoSenior VP/Chief Commercial OfcrAnne M LedouxVP/Chief Acctg Officer
More Company Profile & Key Executives for CORT

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil